Following its debut presentation at IBMS Congress 2011, the
results poster of the Spire Healthcare-commissioned granulocyte and neutrophil
count comparison study of HORIBA Medical's ABX Micros ES 60 and three other
methodologies is now available to view at the HORIBA
Medical-UK website. The study shows that the
granulocyte count of the ABX Micros ES 60 can be considered a neutrophil count
in the absence of flags, making it a suitable instrument for all Point-of-Care
(POC) settings. The neutrophil count is an important parameter in determining
the treatment of oncology and haematology patients.
The aim of the study was to establish that the granulocyte
count of a 3-part differential analyser (ABX Micros ES 60) correlates well when
compared to the neutrophil count of other instruments and methodologies.
Methodology involved the processing of 133 samples, less than four hours old,
by a 5-part differential analyser (the HORIBA Medical ABX Pentra 80) and two
3-part differential analysers, the ABX Micros ES 60 and the PocH-100i (Sysmex).
Manual differential counts were also performed and all results compared.
HORIBA Medical's ABX Micros ES 60 provides a rapid,
laboratory standard full blood count with a 3-part differential. Combined with
the ease of use, small footprint and CPA compliance, it is ideal for the POC
environment. The analyser produces a granulocyte count, consisting of
neutrophils, eosinophils and basophils. The neutrophils make up more than 95%
of the granulocyte population and should, therefore, correlate well with
neutrophil counts from other methodologies in the absence of flags alerting to
elevated eosinophil or basophil levels.
Results from the comparison between the ABX Micros ES 60
and the PocH-100i showed excellent correlation where no flags were present, and
good correlation where there were flags. Additionally, all the instruments involved showed good correlation for neutrophils/granulocytes, particularly in
the absence of flags where there was little distinction between methodologies.
The results from the study dispel any concerns a healthcare practitioner may
have in using a 3-part differential instrument producing a granulocyte count,
as opposed to a neutrophil count.
Working
in partnership with good lines of communication has given rise to additional
future opportunities for both HORIBA Medical and Spire Healthcare. "Having
worked highly effectively with HORIBA Medical for the past year, we know that
we can fully trust their haematology expertise and technology, so much so that
we are now undertaking further joint R&D work," said Clive Woodford,
Pathology Services Manager, Spire. "As part of our policy to always deliver
service excellence to our customers, Spire Healthcare believes that undertaking
applied R&D internally is one means of securing this. We are very pleased
to be working jointly with HORIBA Medical in this area too."
The
results of this comparison study can be viewed in detail at:
www.horiba.com/uk/medical/feedback/poc-analyser-neutrophil-and-granulocyte-comparison-study
Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!
Request your free copies HERE
Popular this Month
Top 10 most popular articles this month
Today's Picks
Looking for a Supplier?
Search by company or by product
Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.
Lab Bulletin is published by newleaf marketing communications ltd.